Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYG-440
- Development stage
- Preclinical
- Lead developer
- GLSynthesis
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HYG-440 is a topical "soft" anti-androgen developed by Hygeia Therapeutics (later acquired by RestorGenex Corporation). The drug was designed using a "soft drug" approach, meaning it is intended to be topically active at the site of application but rapidly metabolized into inactive metabolites upon entering the systemic circulation. This mechanism is designed to treat androgen-mediated dermatological conditions such as acne, hirsutism (excess facial hair), and androgenetic alopecia (hair loss) while minimizing systemic anti-androgenic side effects. The technology for HYG-440 was licensed from Yale University.
- Other names
- soft anti-androgen
Beyond the preview
Go deeper on HYG-440.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYG-440.